Evidence map›Paper›PMID 26888095›Full record

ArticleScientific reports2016

Rapamycin attenuates acute lung injury induced by LPS through inhibition of Th17 cell proliferation in mice.

Zhao Yan, Zhang Xiaoyu, Song Zhixin, Qi Di, Deng Xinyu, Xia Jing, He Jing, Deng Wang, Zhong Xi, Zhang Chunrong and 1 more

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.

0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed
4.5field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

30 citing papers in PubMed, 61 citations in OpenAlex.

  1. Infection and immunity · 2026
    Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Review
  8. Article
  9. Pharmaceuticals (Basel, Switzerland) · 2023
    Article
  10. Article
  11. Article
  12. Development of Adaptive Immunity and Its Role in Lung Remodeling.Advances in experimental medicine and biology · 2023
    Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 1 country.

Zhao YanDepartment of Pulmonary and Critical Care Medicine, the Second Affiliated Hospital of Chongqing Medical University, 76 Linjiang Road, Yuzhong District, Chongqing 400010, China.
Zhang XiaoyuDepartment of Pulmonary and Critical Care Medicine, the Second Affiliated Hospital of Chongqing Medical University, 76 Linjiang Road, Yuzhong District, Chongqing 400010, China.
Song ZhixinKey Laboratory of Diagnostic Medicine Designated by the Ministry of Education, Chongqing Medical University, 1 Yixueyuan Road, Yuzhong District, Chongqing 400010, China.
Qi DiDepartment of Pulmonary and Critical Care Medicine, the Second Affiliated Hospital of Chongqing Medical University, 76 Linjiang Road, Yuzhong District, Chongqing 400010, China.
Deng XinyuDepartment of Pulmonary and Critical Care Medicine, the Second Affiliated Hospital of Chongqing Medical University, 76 Linjiang Road, Yuzhong District, Chongqing 400010, China.
Xia JingDepartment of Pulmonary and Critical Care Medicine, the Second Affiliated Hospital of Chongqing Medical University, 76 Linjiang Road, Yuzhong District, Chongqing 400010, China.
He JingDepartment of Pulmonary and Critical Care Medicine, the Second Affiliated Hospital of Chongqing Medical University, 76 Linjiang Road, Yuzhong District, Chongqing 400010, China.
Deng WangDepartment of Pulmonary and Critical Care Medicine, the Second Affiliated Hospital of Chongqing Medical University, 76 Linjiang Road, Yuzhong District, Chongqing 400010, China.
Zhong XiDepartment of Pulmonary and Critical Care Medicine, the Second Affiliated Hospital of Chongqing Medical University, 76 Linjiang Road, Yuzhong District, Chongqing 400010, China.
Zhang ChunrongDepartment of Emergency Medicine, the Yongchuan Affiliated Hospital of Chongqing Medical University, 439 Xuanhua Road, Yongchuan District, Chongqing 402160, China.
Wang DaoxinDepartment of Pulmonary and Critical Care Medicine, the Second Affiliated Hospital of Chongqing Medical University, 76 Linjiang Road, Yuzhong District, Chongqing 400010, China.
Dalian Medical University · CNSecond Affiliated Hospital of Chongqing Medical University · CNChongqing Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Th17 cells have been confirmed to increase neutrophils through cytokine secretions. ALI/ARDS are characterized as neutrophil infiltration in inflammation cases; however, there is conflicting information concerning the role of Th17 cells in ALI/ARDS, as well as their potential treatment value. We measured Th17-linear cytokines in the plasma of patients with sepsis-related ARDS. The consistently high levels of IL-17 and IL-22 in the nonsurvivors suggested that overreaction of the Th17-mediated immune response may be a risk factor for poor outcomes. Th17 linear cytokines were also increased in an LPS-induced murine model of acute lung injury, along with neutrophil accumulation. The mice that completely lacked IL-17 failed to accumulate and activate neutrophils. Lung inflammation was obviously attenuated in the IL-17(-)/(-) mice. Meanwhile, the neutrophil count was markedly increased in the healthy WT mice challenged with recombinant IL-22 and IL-17. Rapamycin attenuated lung injury by inhibiting the differentiation of Th17 cells through RORγt and STAT3 dysfunction. Furthermore, we demonstrated that SOCS3 and Gfi1, which were responsible for the molecular suppression of RORγt and STAT3, were up-regulated by rapamycin. These results point toward a pivotal view to treatment of ALI through weakening the proliferation of Th17 cells with rapamycin.

Indexed as

Acute Lung InjuryAnimalsCell ProliferationDisease Models, AnimalDNA-Binding ProteinsInterleukin-17Interleukin-22InterleukinsLipopolysaccharidesMaleMiceMice, Inbred BALB CMice, KnockoutNuclear Receptor Subfamily 1, Group F, Member 3SirolimusSTAT3 Transcription FactorDNA-Binding ProteinsGfi1 protein, mouseInterleukin-17Interleukin-22InterleukinsLipopolysaccharidesNuclear Receptor Subfamily 1, Group F, Member 3SirolimusSocs3 protein, mouseStat3 protein, mouseSTAT3 Transcription FactorSuppressor of Cytokine Signaling 3 ProteinTranscription Factors

Identifiers

PMID26888095
PMCPMC4757870
OpenAlexW2293579973

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.